Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 20/07/2022)

1st line
ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

PDC-LUNG-101 (PDC*line)
Safety, Immunogenicity and Preliminary Clinical Activity Study of  PDC*Lung01 Cancer Vaccine in NSCLC.
(cohort B2 open)

ZEAL (GSK)
Placebo-controlled Study Comparing Niraparib (PARP inhibitor) Plus Pembolizumab Versus Placebo Plus Pembrolizumab as Maintance Therapy in Participants with Advanced/Metastatic Non-small Cell Lung Cancer.

2nd line 
CARMEN-LC03 (Sanofi) (after chemo- and immunotherapy)
SAR408701 (tusamitamab ravtansine; ADC) Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients.

ARTEMIDE (AstraZeneca)
A Study to Assess the Safety and Efficacy of AZD2936 (TIGIT/PD-1 bispecific antibody) in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).

ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

3rd line
ARTEMIDE (AstraZeneca)
A Study to Assess the Safety and Efficacy of AZD2936 (TIGIT/PD-1 bispecific antibody) in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).

ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

2nd-3rd-4th line
CARMEN-LC06 (Sanofi)
Open label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine (ADC) in participants with CEACAM5 negative-moderate expression and high circulating CEA non-squamous non-small-cell lung cancer (NSQ NSCLC).